

Claims:

1. A pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.
5
2. The pharmaceutical combination according to claim 1, wherein the first active ingredient is ponesimod and the second active ingredient is teriflunomide.
- 10 3. The pharmaceutical combination according to claim 1, wherein the first active ingredient is ponesimod and the second active ingredient is leflunomide.
4. The pharmaceutical combination according to any one of claims 1 to 3, wherein the first and the second active ingredient are comprised in a single pharmaceutical composition.
15
5. The pharmaceutical combination according to any one of claims 1 to 3, wherein the first and the second active ingredient are comprised in separated pharmaceutical compositions.
- 20 6. Use of a pharmaceutical combination according to any one of claims 1 to 5 in the manufacture of a medicament for the prevention or treatment of a disease or disorder associated with a lymphocyte-mediated activated immune system.
7. Use of a pharmaceutical combination according to any one of claims 1 to 5 in the
25 manufacture of a medicament for the treatment of multiple sclerosis.
8. Use of a pharmaceutical composition containing ponesimod and at least one therapeutically inert excipient in the manufacture of a medicament, for the prevention or
30 treatment of a disease or disorder listed in claim 6 or 7, wherein said medicament is to be administered in combination with a second medicament containing teriflunomide or leflunomide and at least one therapeutically inert excipient.
- 35 9. Use of a pharmaceutical composition containing teriflunomide or leflunomide and at least one therapeutically inert excipient, in the manufacture of a medicament for the

prevention or treatment of a disease or disorder listed in claim 6 or 7, wherein said medicament is to be administered in combination with a second medicament containing ponesimod and at least one therapeutically inert excipient.